Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism

Journal of Immunology

Volumn 171, Issue 5, 2003, Pages 2251-2261

  Xu, Shuwen ^a   Koski, Gary K ^a   Faries, Mark ^a   Bedrosian, Isabelle ^a   Mick, Rosemarie ^a   Maeurer, Markus ^b   Cheever, Martin A ^c   Cohen, Peter A ^d   Czerniecki, Brian J ^a,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c GLAXOSMITHKLINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 100; INTERLEUKIN 12; MELAN A; TUMOR ANTIGEN;

ADULT; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MALE; MELANOMA CELL; NORMAL HUMAN; T LYMPHOCYTE ACTIVATION;

EID: 0042931259     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.5.2251     Document Type: Article

References (45)

1. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
2. Rosenberg, S., Y. Zhai, J. Yang, D. Schwartzentruber, P. Hwu, F. Marincola, S. Topalian, N. Restifo, C. Seipp, J. Einhorn, et al. 1998. Immunizing patients with metastatic melanoma using recombinant endoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1894.
3. Hsu, F., C. Benike, F. Fagnoni, T. Liles, D. Czerwinski, B. Taidi, E. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
4. Heiser, A., D. Coleman, J. Dannull, D. Yancey, M. Maurice, C. Lallas, P. Dahm, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109:409.
5. Jonuleit, H., A. Giesecke-Tuettenberg, T. Tutling, B. Thurner-Schuler, T. Stuge, L. Paragnik, A. Kandemir, P. Lee, G. Schuler, J. Knop, and A. Enk. 2001. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T cell responses in humans following intranodal injection. Int. J. Cancer 93:243.
6. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
7. + tumors. Cancer Res. 58:4902.
8. Kawashima, I., S. Hudson, V. Tsai, S. Southwood, K. Takesako, E. Appella, A. Sette, and E. Celis. 1998. The multiepitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on epithelial tumors. Hum. Immunol. 59:1.
9. Lechler, R., and J. Batchelor. 1982. Restoration of immunogenicity to passenger-depleted kidney allografts by the addition of donor strain dendritic cells. J. Exp. Med. 155:31.
10. Inaba, K., J. Metlay, M. Crowley, and R. M. Steinman. 1990. Dendritic cells pulsed with protein antigens in vitro can prime antigen specific MHC restricted T cells in situ. J. Exp. Med. 172:631.
11. + T cells by infected dendritic cells in vivo. Nat. Immunol. 3:265.
12. + T cells by exogenous dell-associated antigens. Immunity 17:211.
13. Mosmann, T., H. Chcrwinski, M. Bond, M. Giedlin, and R. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348.
14. Rissoan, M.-C., V. Soumelis, N. Kadowaki, G. Grouard, F. Briere, R. de Wall Malefyt, and Y.-J. Liu. 1999. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283:1183.
15. Whelan, M., M. Harnett, K. Houston, V. Patel, W. Harnett, and K. Rigley. 2000. A filarial nematode-secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells. J. Immunol. 164:6453.
16. Vieira, P., E. de Jong, E. Wierenga, M. Kapsenberg, and P. Kalinski. 2000. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol. 164:4507.
17. de Jong, E., P. Vieira, P. Kalinski, J. Schuitemaker, Y. Tanaka, E. Wierenga, M. Yazdanbakhsh, and M. Kupsenberg. 2002. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J. Immunol. 168:1704.
18. Snijders, A., P. Kalinski, C. Hilkens, and M. Kapsenberg. 1998. High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. 10:1593.
19. + dendritic cells that induce Th2 development. Blood 98:2489.
20. Czerniecki, B., C. Carter, L. Rivoltini, G. Koski, H. Kim, D. Weng, J. Roros, Y. Hijazi, S. Xu, S. Rosenberg, and P. Cohen. 1997. Calcium ionophore treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J. Immunol. 159:3823.
21. Mantel, N., and W. Haenzel. 1959. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22:719.
22. Andrew, D., M. Chang, J. McNinch, S. Wathen, M. Rihanek, J. Tseng, J. Spellberg, and C. Elias. 1998. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J. Immunol. 161:5027.
23. + monocyte derived dendritic cells and the implications for cancer vaccines. Crit. Rev. Immunol. 21:157.
24. Zitvogel, L., B. Couderc, J. I. Mayordomo, P. D. Robbins, M. T. Lotze, and W. J. Storkus. 1996. IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann. NY Acad. Sci. 795:284.
25. Douin-Echinard, V., P. Robbins, M. Lotze, G. Favre, and B. Couderc. 1998. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70. Adv. Exp. Med. Biol. 451:353.
26. Fallarino, F., C. Uyttenhove, T. Boon, and T. Gajewski. 1999. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine IL-12. Int. J. Can. 80:324.
27. Schuler-Thurner, B., E. Schultz, T. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved peptide-loaded monocyte derived dendritic cells. J. Exp. Med. 195:1279.
28. 2 results in uniform maturation of human monocyte-derived dendiitic cells: implications for immunotherapy. Vaccine 20:A8.
29. Dauer, M., B. Obermaier, J. Herten, C. Haerle, K. Pohl, S. Rothenfusser, M. Schnurr, S. Endres, and A. Eigler. 2003. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170:4069.
30. Cawthon, A., and M. Alexander-Miller. 2002. Optimal colocalization of TCR and CD8 is a novel mechanism for the control of functional avidity. J. Immunol. 169:3492.
31. Winzler, C., P. Rovere, M. Rescigno, F. Granuci, G. Penna, L. Adnori, V. Zimmerman, J. Davoust, and P. Ricciardi-Castagnoli. 1997. Maturation stages of mouse dendritic cells in growth factor-dependent long term cultures. J. Exp. Med. 185:317.
32. Labeur, M. S., B. Roters, B. Pers, A. Mehling, T. A. Luger, T. Schwarz, and S. Grabbe. 1999. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162:168.
33. Dhodapkar, M., R. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193:233.
34. Dhodapkar, M., J. Young, P. Chapman, W. Cox, J. Fonteneau, S. Amigorena, A. Houghton, R. Steinman, and N. Bhardwaj. 2000. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin. Cancer Res. 6:4831.
35. Yang, S., G. Linette, S. Longrich, and F. Haluska. 2002. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 G209-2M is correlated with TCR avidity. J. Immunol. 169:531.
36. Columbo, M., and G. Trinchieri. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:155.
37. + melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant interleukin 12. Clin. Cancer Res. 7:895s.
38. + CTL responses in vitro. J. Clin. Invest. 98:715.
39. Alonso, M., and J. Millan. 2001. The role of lipid rafts in signalling and membrane trafficking in T lymphocytes. J. Cell Sci. 114:3957.
40. Cherukuri, A., M. Dykstra, and S. Pierce. 2001. Floating the raft hypothesis: lipid rafts play a role in immune cell activation. Immunity 14:657.
41. lck adducts in rafts. Eur. J. Immunol. 5:1561.
42. Xavier, R., T. Brennan, Q. Li, C. McCormack, and B. Seed. 1998. Membrane compartmentation is required for efficient T cell activation. Immunity 8:723.
43. Alexander-Miller, M., G. Leggatt, and J. Berzofsky. 1996. Selective expression of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. 93:4102.
44. Zeh, H., D. Pery-Lalley, M. Dudley, S. Rosenberg, and J. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989.
45. Oh, S., J. Hodge, J. Ahlers, D. Burke, J. Schlom, and J. Berzofsky. 2003. Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 170:2523.